{"entity":{"id":"nct07828756","kind":"trial","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of cisplatin, nab-paclitaxel, capecitabine and gemcitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer is a phase 2, interventional study registered as NCT07828756 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 147 participants, started 2026-09-30 and due to reach its primary completion in 2027-10-31. Interventions recorded: Cisplatin; Albumin-bound Paclitaxel (II); Albumin-bound Paclitaxel (II); Capecitabine; Capecitabine; Gemcitabine; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS); 1-Year Event-Free Survival Rate (1y-EFS Rate); Recommended Phase 2 Dose (RP2D). Pancreatic eligibility wording from the registry: \"* Histopathologically confirmed pancreatic adenocarcinoma meeting any one of the following conditions: (1) Unresectable locally advanced or metastatic pancreatic cancer, with no prior systemic anti-tumor therapy for advanced disease\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07828756","url":"https://clinicaltrials.gov/study/NCT07828756"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin","nab-paclitaxel","capecitabine","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07828756","phase":"2","setting":"A Multi-cohort Exploratory Study to Evaluate the Efficacy and Safety of Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":147,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07828756/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}